Cardiogen vs TB-500
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in nearly all human and animal cells. It promotes cell migration to injury sites, accelerates tissue regeneration, and reduces chronic inflammation.
- Half-Life
- Short (minutes); gene-regulatory effects persist longer
- 2–3 hours
- Admin Route
- SubQ, Oral
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 2–2.5 mg
- Frequency
- Daily for 10–30 days
- Twice weekly
- Key Benefits
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Enhances muscle tissue regeneration
- Accelerates healing of wounds and injuries
- Reduces inflammation and pain
- Improves flexibility and mobility
- Promotes new blood vessel formation
- Supports hair growth and skin health
- May improve cardiac function after injury
- Systemic healing effect — works at distance from injection site
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Injection site discomfort
- Fatigue (rare)
- Headache (rare)
- Stacks With
- —
- —